Literature DB >> 1708700

Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

M Micallef1, M Hosokawa, T Shibata, A Nakane, Z B Yang, T Minagawa, H Kobayashi.   

Abstract

We have studied the immunological effects that accompany a change in the chemical structure of a group of antineoplastic antibiotics by comparing the immunoregulatory cytokine release during mitogen-stimulated spleen cell culture after in vivo drug treatment. Whereas bleomycin and peplomycin increased cytokine levels in culture supernatants when compared with supernatants from untreated control rat spleen cell cultures, liblomycin generally reduced cytokine levels under the same culture conditions. We then compared these results with the antitumor effects of equivalent doses of the three drugs against a highly antigenic rat fibrosarcoma, KMT-17, both in vivo and in vitro. The results suggest that the immunoaugmenting effects of these antitumor antibiotics are essential for an optimal antitumor effect in vivo, and that these effects can be drastically altered by modification of the chemical structure of the drugs employed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708700     DOI: 10.1007/bf01742525

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma.

Authors:  K Morikawa; M Hosokawa; J Hamada; M Sugawara; H Kobayashi
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

2.  Potentiation of release of interleukin-2 by bleomycin.

Authors:  T A Abdul Hamied; D Parker; J L Turk
Journal:  Immunopharmacology       Date:  1986-10

3.  DNA cleavage activity of liblomycin (NK313), a novel analog of bleomycin.

Authors:  H Kuramochi; A Motegi; K Takahashi; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1988-12       Impact factor: 2.649

4.  Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.

Authors:  H S Schwartz; G B Grindey
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

7.  Fluorinated 4-quinolones induce hyperproduction of interleukin 2.

Authors:  K Riesbeck; J Andersson; M Gullberg; A Forsgren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

8.  Possible participation of tumoricidal macrophages in the therapeutic effect of bleomycin on a transplantable rat fibrosarcoma.

Authors:  K Morikawa; M Hosokawa; J Hamada; Z Y Xu; H Kobayashi
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

9.  Rat T lymphocyte antigens comparable with mouse Lyt-1 and Lyt-2,3 antigenic systems: characterization by monoclonal antibodies.

Authors:  A Matsuura; Y Ishii; H Yuasa; H Narita; S Kon; T Takami; K Kikuchi
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

10.  Potentiation of T-lymphocyte function by bleomycin.

Authors:  D Parker; J L Turk
Journal:  Immunopharmacology       Date:  1984-04
View more
  3 in total

1.  Rat macrophage activation after treatment with the bleomycin group of antitumour antibiotics in vivo.

Authors:  M Micallef; M Hosokawa; Y Togashi; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  CP-115,953 stimulates cytokine production by lymphocytes.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.

Authors:  L Yuan; Y Kuramitsu; Y Li; M Kobayashi; M Hosokawa
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.